Hims & Hers Health (NYSE: HIMS) shares rose more than 7% in premarket trading Friday after the telehealth company and Eli Lilly announced an agreement…
November 06, 2026
Key Points LifeMD’s affiliated pharmacy can directly dispense and ship Lilly’s Zepbound and Foundayo to eligible patients nationwide. Patients can purchase prescribed medicines through LifeMD…
Key Points Hims & Hers reported accelerating domestic revenue growth and international expansion, while raising its 2026 revenue outlook. Management reiterated 2030 targets of at…
Key Points Oral SKNY-1 significantly reduced body weight and fat mass compared with vehicle-treated controls in an exploratory mouse study. Weight reduction occurred without a…
Key Points Amylyx will present Phase 3 LUCIDITY topline results for avexitide at ObesityWeek 2026 on November 15. The company previously announced positive topline results…
July 30, 2026
Viking Therapeutics (NASDAQ: VKTX): The Next Obesity Catalyst May Be About Staying on Therapy
Key Highlights Phase 3 enrollment for injectable VK2735 is complete, with maintenance dosing data expected later this quarter. Oral Phase 3 development remains on track…
Fractyl Health Inc. (NASDAQ: GUTS) is highlighting new REMAIN‑1 data that suggest its Revita procedure may help people maintain much of their weight loss for…
June 03, 2026
Women on Ozempic‑Like Drugs Saw Lower Breast Cancer Rates – What It Means for GLP‑1 Investors
A large Penn Medicine analysis found that women taking GLP‑1 drugs such as Ozempic and Wegovy from Novo Nordisk (NYSE: NVO), and Mounjaro or Zepbound…
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has released new interim clinical data showing that its experimental obesity and liver disease drug ARO‑INHBE meaningfully cuts liver fat…
Novo Nordisk (NYSE: NVO) is launching an oral version of Ozempic for adults with type 2 diabetes in the U.S. starting May 4, 2026. The…
Structure Therapeutics Inc. (NASDAQ: GPCR) just delivered some of the strongest weight‑loss data yet for an oral GLP‑1, instantly elevating its M&A appeal in the…
Novo Nordisk (NYSE: NVO) has reached an agreement with Hims & Hers Health, Inc. (NYSE: HIMS) that will allow the telehealth company to distribute Novo…